Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression

(2017) Michal Šmahel   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

(2017) Vikram R. Juneja et al.   JOURNAL OF EXPERIMENTAL MEDICINE

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

(2017) Janet Lau et al.   Nature Communications

A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy

(2017) Yohei Takeda et al.   Cell Reports

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

(2017) Takuro Noguchi et al.   Cancer Immunology Research

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy

(2017) Jan Willem Kleinovink et al.   OncoImmunology

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis

(2016) Andrea Schietinger et al.   IMMUNITY

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

(2016) K. E. Pauken et al.   SCIENCE

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Role of memory T cell subsets for adoptive immunotherapy

(2016) Dirk H. Busch et al.   SEMINARS IN IMMUNOLOGY

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Overcoming T cell exhaustion in infection and cancer

(2015) Kristen E. Pauken et al.   TRENDS IN IMMUNOLOGY

Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo

(2015) Misako Matsumoto et al.   Nature Communications

Accumulation of cytolytic CD8+ T cells in B16-melanoma and proliferation of mature T cells in TIS21-knockout mice after T cell receptor stimulation

(2014) Min Sook Ryu et al.   EXPERIMENTAL CELL RESEARCH

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

(2014) S. D. Brown et al.   GENOME RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Tumor-Altered Dendritic Cell Function: Implications for Anti-Tumor Immunity

(2013) Kristian M. Hargadon   Frontiers in Immunology

Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants

(2011) Karen M. Kaluza et al.   INTERNATIONAL JOURNAL OF CANCER

Memories that last forever: strategies for optimizing vaccine T-cell memory

(2009) J. D. Ahlers et al.   BLOOD